Entry Detail



General Information

Database ID:exR0274569
RNA Name:hsa-miR-181c-5p
RNA Type:miRNA
Chromosome:chr19
Starnd:+
Coordinate:
Start Site(bp):13874725End Site(bp):13874746
External Links:hsa-miR-181c-5p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE22981
Description:Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:Early satge breast cancer
Case Sample:Breast Cancer
Control Sample:Control
Number of Case:20
Number of Control:20
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
GALNT10
chr5
154190730
154420984
+
IGF2BP3
chr7
23310209
23470491
-
IRS2
chr13
109752695
109786583
-
NSMAF
chr8
58583508
58659853
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001550
chr5
167915606
167921655
+
hsa_circ_0000540
chr14
55799534
55821940
+
hsa_circ_0001522
chr5
122881110
122893258
+
hsa_circ_0000892
chr19
11941431
12014514
+
hsa_circ_0001361
chr3
171830241
171851336
+
hsa_circ_0000931
chr19
38226804
38231095
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC010442.1
chr5
466124
473098
-
AC010655.4
chr7
128455840
128493859
+
AC021078.1
chr5
149494314
149504670
-
AC144548.1
chr12
110387463
110445548
-
AL035458.2
chr20
34234840
34281173
-
AL049543.1
chr6
28587378
28591747
+
KCNQ1OT1
chr11
2608328
2699994
-
LINC00667
chr18
5237826
5290608
+
MALAT1
chr11
65497688
65506516
+
MIR4458HG
chr5
8450701
8486930
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
OIP5-AS1
chr15
41283990
41309737
+
SNHG1
chr11
62851984
62855953
-
SNHG5
chr6
85650491
85678932
-
SNHG7
chr9
136721366
136728184
-
THUMPD3-AS1
chr3
9349689
9398579
-
XIST
chrX
73820649
73852723
-
ZSCAN16-AS1
chr6
28015122
28137293
-
Display:



Experiment Detail

GEO ID:GSE22981
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL8179
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:801
Sample treatment protocol:NA
RNA Extract protocol:Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications.
RNA library preparation protocol:Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).



Reference

PMID:21060830
Title:A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer
Author:Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
Journal:PLoS One. 2010 Oct 29;5(10):e13735.
Description:The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.